OncoACP3 

OncoACP3 is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC₅₀ of 0.30 nM. OncoACP3 has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 is applicable to research related to prostate cancer^[1].

OncoACP3 binds to human recombinant ACP3 with ultra-high affinity, with a dissociation rate of 1.2 × 10^-4 s^-1[1].
¹⁷⁷Lu-OncoACP3 specifically binds to HT1080.hACP3 and PC3.hACP3 cells expressing ACP3, but does not bind to ACP3-negative wild-type cells^[1].
¹⁷⁷Lu-OncoACP3 specifically localizes to the membranes of HT1080.hACP3 and PC3.hACP3 cells that express ACP3, but does not bind to wild-type cells without ACP3 expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

¹⁷⁷Lu-OncoACP3 (250-1000 MBq/kg, i.v., single administration) induces potent antitumor activity and even complete cure in tumor-bearing mice^[1].
OncoACP3 is conjugated to the cytotoxic agent MMAE (HY-15162) via a cleavable linker to construct the small-molecule drug conjugate OncoACP3-GlyPro-MMAE, which enables targeted chemotherapy in mouse models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1209.33

C₆₀H₈₁N₁₂O₁₃P

3084147-81-6

OC(CN1CCN(CC(NCCCCCCNC([C@H]2N(C(CN(CC3=CC=CC=C3)CC4=CC=CC=C4)=O)C[C@@H](N5N=NC(COC6=CC=C(C(NCC7=CC=CC=C7)P(O)(O)=O)C=C6)=C5)C2)=O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Georgiev T, et al. Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy. Nat Biomed Eng. 2026;10(1):178-191.  [Content Brief]